Bottom line from the web. Cooper is in the middle of a live, dual-front activist campaign that the 10-K and the proxy cannot fully capture: Jana Partners disclosed a $167M / 1.22%-of-company stake in late 2025 pushing to sell CooperVision to Bausch+Lomb, while Browning West (>$500M invested) is separately demanding the opposite trade — sell CooperSurgical and keep a pure-play vision company. The board has already settled with Browning West (Walt Rosebrough appointed Jan 3, 2026; likely Board Chair by end of 2026), Colleen Jay took over as Chair in January 2026, and Bausch+Lomb CEO Brent Saunders has publicly volunteered that a vision combination would "strengthen competition." The filings show a slowing compounder; the web shows a company whose corporate structure is explicitly in play.
**#1 — Dual activist campaign with a director already seated.** Jana Partners bought 2,434,607 shares (Q3 2025, ~$166.9M, 8.08% of its portfolio) and is publicly pushing a CooperVision / Bausch+Lomb combination; Browning West holds >$500M and nominated four directors (Rosebrough, Joe Papa, Andy Pawson, Faraz Athar). On December 23, 2025 Cooper signed a cooperation agreement with Browning West, appointed Walt Rosebrough (18% annualized TSR as STERIS CEO 2007-2021) effective January 3, 2026, and committed to "due and serious consideration" of Rosebrough as Board Chair by year-end 2026 plus a second medtech-experienced director to be chosen with Browning West's consent. This is materially more concrete than "activist agitation" — Cooper has already ceded board composition rights. Sources: [globenewswire.com/CooperCompanies-Appoints-Walter-M-Rosebrough-Jr](https://www.globenewswire.com/news-release/2025/12/23/3209824/2200/en/CooperCompanies-Appoints-Walter-M-Rosebrough-Jr-to-its-Board-of-Directors.html), [cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html), [fiercebiotech.com/cooper-companies-under-activist-pressure-split-different-ways](https://www.fiercebiotech.com/medtech/cooper-companies-under-activist-pressure-split-different-ways).
**#2 — Bausch+Lomb's CEO is publicly inviting a deal.** Brent Saunders, a serial dealmaker, has stated on-record that combining with CooperVision would "strengthen competition and create a more scaled company in the contact lens segment." Jana's synergy estimate: $300-500M on $850M of CVI EBITDA. The combined global soft-lens share (~36%) would still sit just below market leader J&J (37%), which Jana's research argues minimizes antitrust risk. Source: [cnbc.com/2025/11/15](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html), [stocktwits.com/activist-investor-turns-up-heat](https://stocktwits.com/news-articles/markets/equity/activist-investor-turns-up-heat-on-cooper-urges-bausch-lomb-merger-to-boost-returns-report/ch6CWJvR3oK).
**#3 — The Cook Medical deal the filings allude to was terminated by FTC pressure, not closed.** The specialist writeups reference "Cook Medical integration costs" in CSI margins — but the original $875M Cook Medical reproductive-health acquisition (signed Feb 2022) was abandoned on August 1, 2023 after a full-phase FTC investigation concluded it would reduce competition in critical reproductive health markets. CooperSurgical later came back with a "doubled-back" slimmed-down deal, but the original thesis of a 2-year Cook subsidiary production transition was killed. This reframes the last three years of CSI ROIC drag: the capital was spent on the walk-away termination, integration redo, and smaller scope — not a completed acquisition that simply underperformed. Sources: [ftc.gov/statement-regarding-termination](https://www.ftc.gov/news-events/news/press-releases/2023/08/statement-regarding-termination-coopercompanies-attempted-acquisition-cook-medicals-reproductive), [massdevice.com/cooper-abandons-cook-medical-reproductive-acquisition](https://www.massdevice.com/cooper-abandons-cook-medical-reproductive-acquisition/), [fiercebiotech.com/after-ftc-scrutiny-coopersurgical-calls-875m-deal](https://www.fiercebiotech.com/medtech/after-ftc-scrutiny-coopersurgical-calls-875m-deal-cook-medicals-reproductive-health).
**#4 — MiSight Japan launched February 10, 2026, with 77% pediatric myopia prevalence as the addressable base.** CooperVision is now the only soft contact lens authorized in Japan for pediatric myopia control (US, China, Japan all approved). Up to 77% of Japanese elementary-school-aged children are myopic per MHLW/industry estimates — a much larger addressable pool than the ~40% figure used in most US modeling. Management called out MiSight +37% in Q4 FY25; the Japan launch adds a structurally different market. This is an under-appreciated growth option the market is treating as incremental. Source: [reachmd.com/coopervisions-misight-1-day-becomes-first-pediatric-myopia-control-contact-lens-available-in-japan](https://reachmd.com/news/coopervisions-misight-1-day-becomes-first-pediatric-myopia-control-contact-lens-available-in-japan/2485642/), [reviewofmm.com/misight-1-day-approval-in-japan](https://reviewofmm.com/misight-1-day-approval-in-japan/).
**#5 — Paragard's 40-year monopoly ended in February 2025.** The FDA approved Miudella (Sebela Women's Health), the first new hormone-free copper IUD since Paragard's original 1984 approval. Miudella uses less than half the copper, a 3.7mm flexible-nitinol insertion device, and a 3-year indication — directly addressing the "painful insertion" objection that drove some market share to hormonal alternatives. Sebela is planning broad US availability during 2026. Cooper disclosed a mid-teens decline in Paragard sales in Q2 FY25; the competitive runway just narrowed materially. Sources: [futurefemhealth.com/fda-approves-first-new-hormone-free](https://www.futurefemhealth.com/p/fda-approves-first-new-hormone-free), [medicine.iu.edu/2026-bernard-iud-clinical-trial-indiana](https://medicine.iu.edu/blogs/indiana-health/2026-bernard-iud-clinical-trial-indiana).
**#6 — Insider buying sits above $2.5M with zero sales; Rosebrough appointment was met with a 12% after-hours pop on Dec 3, 2025.** The ten open-market insider purchases in 2025 (led by CEO White putting $1.49M across two tranches) were not isolated — they preceded and followed both the Q3 FY25 guidance-cut sell-off and the Jana announcement. When the Q4 FY25 print on December 3, 2025 bundled a strategic review signal, a new Chair announcement (Colleen Jay), and an $89M reorganization charge translating to $50M in annual savings, the stock rose 12% after-hours. Message from the tape: the market is pricing the activist outcome as a positive, not a threat. Source: [gurufocus.com/cooper-cos-coo-surges-on-strategic-review-and-leadership-change](https://www.gurufocus.com/news/3234968/cooper-cos-coo-surges-on-strategic-review-and-leadership-chan).
**#7 — Q3 FY25 was the credibility break; Trump IVF-coverage comments the unexpected culprit.** Organic growth fell to 2% in Q3 FY25 from 7% the prior quarter; Cooper cut full-year guidance and the stock dropped 12.85% the next day. Jana's research attributed the fertility deceleration specifically to President Trump's public comments suggesting potential Federal reimbursement of IVF costs — prompting patients to delay cycles in anticipation of coverage. This is a political-risk narrative the specialists flagged but could not source externally; the web confirms it. Source: [cnbc.com/2025/11/15](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html).
**#8 — Goldman Sachs initiated with a Sell on October 1, 2025; JP Morgan cut PT to $66 (from $76) on August 28, 2025.** Sell-side sentiment is divided and skewing negative heading into the activist campaign. The current 17-analyst consensus target is $85.80 (range $64-$98). The Goldman Sell call (analyst David Roman, PT $64) puts a material downside anchor below the current price. Needham is the most bullish at the top end of the range (PT $94, raised June 17, 2025). Source: [gurufocus.com/goldman-sachs-initiates-coverage-on-cooper-companies-with-a-sell-rating](https://www.gurufocus.com/news/3127863/goldman-sachs-initiates-coverage-on-cooper-companies-coo-with), [defenseworld.net/cooper-companies-sets-new-52-week-low-on-analyst-downgrade](https://www.defenseworld.net/2025/08/29/cooper-companies-nasdaqcoo-sets-new-52-week-low-on-analyst-d).
**#9 — Tariffs are a live, disclosed gross-margin headwind into FY26.** Q4 FY25 non-GAAP gross margin was 66% (down 70 bps YoY) on tariffs and mix; Q2 FY25 disclosed ~$4M tariff cost of goods in-year, with management noting a "more complex global operating environment." Cooper manufactures through Costa Rica, Hungary, Puerto Rico, the UK, Belgium and the US — exactly the footprint exposed to US reciprocal tariffs (Section 232 ripple effects) and the 2025 "Liberation Day" tariff regime. KPMG's Q3 2025 executive survey: 32% of US companies reporting 1-5% gross margin decline, 22% reporting 6-10% — Cooper's disclosed impact is toward the lighter end, but the full-year FY26 rate depends on tariff regime persistence. Source: [ainvest.com/cooper-companies-slowing-growth-strategic-implications](https://www.ainvest.com/news/cooper-companies-slowing-growth-strategic-implications-long-term-2509/), [kpmg.com/tariff-business-impact-what-executives-think-now](https://kpmg.com/us/en/articles/2025/tariff-business-impact-what-executives-think-now.html).
**#10 — First-ever three-year free cash flow commitment: $2.2B+ FY26-FY28.** On the December 4, 2025 Q4 call, management issued the first explicit multi-year FCF guide in the company's history — over $2.2B of cumulative FCF from FY26 through FY28 — alongside the tripled $2B buyback authorization. This is the "new contract with investors" Jana's campaign helped force. In a breakup scenario, that FCF commitment becomes the floor for what the standalone pieces have to clear. Source: [insidermonkey.com/cooper-companies-q4-2025-earnings-call-transcript](https://www.insidermonkey.com/blog/the-cooper-companies-inc-nasdaqcoo-q4-2025-earnings-call-transcript-1655236/), [fool.com/earnings/call-transcripts/2026/03/05/cooper-coo-q1-2026-earnings-call-transcrip](https://www.fool.com/earnings/call-transcripts/2026/03/05/cooper-coo-q1-2026-earnings-call-transcrip).
What the two plans have in common. Both agree Cooper's current structure is worth less than the sum of the parts. Both agree the CEO transition should bring a vision-native operator. Neither is asking for a dividend hike or a leverage cut. The disagreement is which segment goes — and that is a resolution question, not a thesis question. Both paths point to a break-up event within 12-24 months.
What the board has done. On December 23, 2025 Cooper signed a cooperation agreement with Browning West appointing Walt Rosebrough — a candidate Browning West had already nominated — to the board effective January 3, 2026, onto the Corporate Governance & Nominating Committee, with an explicit commitment to "provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board by the end of 2026" and to identify a second medtech-experienced director with Browning West's mutual agreement. Colleen Jay (P&G ex-Global Division President; director since 2016) became Board Chair in January 2026. Jana's plan has no such settlement yet; at the April 7, 2026 annual meeting all nine incumbent directors were re-elected and Say-on-Pay passed, so Jana's campaign is still in the "advisory" phase.
The split matters. Goldman's Sell at $64 is roughly current stock price — i.e., the bear seat is at the market, not below it. Needham's $94 prices roughly the Jana / activist resolution bull case with no operational heroics. The ~$34 range between bear and bull is unusually wide for a medtech large-cap and reflects the binary nature of the activist outcome: if a CVI breakup happens, $94+ is defensible; if management successfully rebuffs, Goldman's $64 is plausible.
Total 2025 insider open-market activity: 10 buys, 0 sells, $2,520,761 deployed. The pattern spans both sides of the Jana announcement — management bought before Jana was public and continued buying after. CEO White's two buys alone total $1.49M. All five NEOs (White, Andrews, McBride, Sheffield, Warner) participated, plus four independent directors. The tape did not find 10b5-1 plan disclosures for the White transactions specifically — timing and pricing are consistent with discretionary conviction buys rather than mechanical ones.
Jana Partners' ownership trajectory. Q3 2025 13F: 2,434,607 shares ($166.9M). Q4 2025 13F: 3,507,075 shares ($289M, +44% QoQ). COO is now Jana's 2nd-largest portfolio position at 15% of a $1.9B AUM. Jana is a net buyer of COO even as the position appreciates — a conviction signal consistent with the "push harder" activist playbook.
Contact lens category growth is decelerating to 4-6% in 2025, not 7-8%. The category-size estimates vary by research house ($11B Fortune Business Insights / $15.6B Research Nester / $20B GM Insights) but consensus CAGR has compressed from "high single digit" to "5-7%" globally. Silicone hydrogel / daily disposables remain the premium-mix driver (daily disposable segment projected 12.5% CAGR vs category 5-7%). North America still dominates at ~34-40% share. The relevant question isn't whether contact lenses are a good industry — they are — but whether the three leaders (J&J, Alcon, CooperVision) can keep taking price in a decelerating volume backdrop. CooperVision's FY25 organic gap vs category (-1-2 points) is real but not catastrophic.
IVF is structurally attractive but politically sensitive. $2B global market growing 4-6%, with aging-mother demographics providing a 15-year tailwind. Near-term: the Trump administration's public suggestion of Federal IVF coverage has created a "wait for potential reimbursement" air pocket in US demand. This is a pure timing headwind, not a demand destruction signal, and it will normalize once the policy question resolves either way.
Private equity is actively buying women's health platforms. Blackstone and TPG were reported as nearing a deal for Hologic (women's health diagnostics peer) — a data point that bolsters Jana's alternative plan of a private-equity-led CooperSurgical carve-out if management resists the CVI sale path. This is an active bidding environment, not a hypothetical one.
Tariffs are a top-of-mind margin headwind across med-tech. Per KPMG's Q3 2025 executive survey, 57% of US companies report 1-10% gross margin declines from the 2025 tariff regime. Cooper's Costa Rica / Hungary / UK / Belgium footprint is directly exposed but disclosed FY25 impact was only ~$4M COGS — at the lighter end of the industry distribution. FY26 impact will depend on reciprocal-tariff regime evolution.
Methodology note. This section synthesizes 42 Brave Search queries across 226 fetched pages (106 from phase-1 specialist-aligned research + 120 from phase-2 targeted specialist questions). Where claims contradict the filing-based specialist analysis, the contradiction is called out explicitly. Where the web is thin, the limit is called out. No speculation beyond what the sources state.